Isatuximab is an investigational anti-CD38 monoclonal antibody with distinct mechanisms of action that are believed to promote programmed tumor cell death and immunomodulatory activity.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
February 01, 2019
Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months. These results demonstrate potential meaningful clinical activity and a manageable safety profile of isatuximab plus pomalidomide/dexamethasone in heavily pre-treated patients with RRMM. The 10 mg/kg QW/Q2W isatuximab dose was selected for future studies.